250 related articles for article (PubMed ID: 17383238)
21. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
22. Sex differences in opioid-mediated pain inhibitory mechanisms during the interphase in the formalin test.
Gaumond I; Spooner MF; Marchand S
Neuroscience; 2007 Apr; 146(1):366-74. PubMed ID: 17306464
[TBL] [Abstract][Full Text] [Related]
23. Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains.
Pick CG; Nejat RJ; Pasternak GW
J Pharmacol Exp Ther; 1993 Apr; 265(1):166-71. PubMed ID: 8386234
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia.
Johnston IN; Westbrook RF
Behav Brain Res; 2005 Jan; 156(1):75-83. PubMed ID: 15474652
[TBL] [Abstract][Full Text] [Related]
25. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
27. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats.
Cook CD; Nickerson MD
J Pharmacol Exp Ther; 2005 Apr; 313(1):449-59. PubMed ID: 15608071
[TBL] [Abstract][Full Text] [Related]
28. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
29. Supraspinal antinociceptive effect of apelin-13 in a mouse visceral pain model.
Lv SY; Qin YJ; Wang NB; Yang YJ; Chen Q
Peptides; 2012 Sep; 37(1):165-70. PubMed ID: 22732665
[TBL] [Abstract][Full Text] [Related]
30. Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration.
Craft RM; Henley SR; Haaseth RC; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1995 Dec; 275(3):1535-42. PubMed ID: 8531126
[TBL] [Abstract][Full Text] [Related]
31. Effect of morphine on deep dorsal horn projection neurons depends on spinal GABAergic and glycinergic tone: implications for reduced opioid effect in neuropathic pain.
Chen YP; Chen SR; Pan HL
J Pharmacol Exp Ther; 2005 Nov; 315(2):696-703. PubMed ID: 16033910
[TBL] [Abstract][Full Text] [Related]
32. Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse.
Vaught JL; Mathiasen JR; Raffa RB
J Pharmacol Exp Ther; 1988 Apr; 245(1):13-6. PubMed ID: 2834533
[TBL] [Abstract][Full Text] [Related]
33. Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model.
Bedini A; Baiula M; Gentilucci L; Tolomelli A; De Marco R; Spampinato S
Peptides; 2010 Nov; 31(11):2135-40. PubMed ID: 20713109
[TBL] [Abstract][Full Text] [Related]
34. Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists.
Sevostianova N; Danysz W; Bespalov AY
Eur J Pharmacol; 2005 Nov; 525(1-3):83-90. PubMed ID: 16297905
[TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
36. Synergistic analgesic effects between neuronostatin and morphine at the supraspinal level.
Yang SB; Yang AM; Shao TJ; Su SF; Chen Q
Peptides; 2013 Jun; 44():105-10. PubMed ID: 23548325
[TBL] [Abstract][Full Text] [Related]
37. Contribution of Endogenous Spinal Endomorphin 2 to Intrathecal Opioid Antinociception in Rats Is Agonist Dependent and Sexually Dimorphic.
Kumar A; Liu NJ; Madia PA; Gintzler AR
J Pain; 2015 Nov; 16(11):1200-10. PubMed ID: 26342648
[TBL] [Abstract][Full Text] [Related]
38. Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine.
Shimoyama M; Szeto HH; Schiller PW; Tagaito Y; Tokairin H; Eun Cm; Shimoyama N
Pharmacology; 2009; 83(1):33-7. PubMed ID: 18987489
[TBL] [Abstract][Full Text] [Related]
39. Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.
Janas A; Folwarczna J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):175-185. PubMed ID: 27896372
[TBL] [Abstract][Full Text] [Related]
40. Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist.
Tive LA; Pick CG; Paul D; Roques BP; Gacel GA; Pasternak GW
Eur J Pharmacol; 1992 Jun; 216(2):249-55. PubMed ID: 1327812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
